Nusinersen is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy, working by modulating SMN2 gene splicing to enhance survival motor neuron protein production. This category… Read more
Nusinersen is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy, working by modulating SMN2 gene splicing to enhance survival motor neuron protein production. This category contains high-quality reference standards essential for pharmaceutical analysis, including Nusinersen active pharmaceutical ingredients, identified process-related impurities, and degradation products. Laboratories utilize these materials for rigorous impurity profiling and method validation, ensuring the accuracy of analytical procedures throughout drug development and manufacturing. Additionally, the inclusion of stable isotope labelled compounds provides critical internal standards for quantitative analysis using mass spectrometry. By providing access to these specialized compounds, researchers and quality control departments can effectively monitor drug quality, support regulatory compliance, and ensure the consistent performance of analytical testing protocols for this complex therapeutic modality.